A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination (Q30418715)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

21 June 2017

A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination (English)

1 reference

Europe PubMed Central

21 June 2017

Otfried Kistner

7

object named as

Otfried Kistner

1 reference

Europe PubMed Central

21 June 2017

9

object named as

Thomas R Kreil

1 reference

Europe PubMed Central

21 June 2017

Helga Savidis-Dacho

2

object named as

Helga Savidis-Dacho

1 reference

Europe PubMed Central

21 June 2017

8

object named as

P Noel Barrett

1 reference

Europe PubMed Central

21 June 2017

author name string

Nicolas Sabarth

1

1 reference

Europe PubMed Central

21 June 2017

Michael G Schwendinger

3

1 reference

Europe PubMed Central

21 June 2017

Peter Brühl

4

1 reference

Europe PubMed Central

21 June 2017

Daniel Portsmouth

5

1 reference

Europe PubMed Central

21 June 2017

Brian A Crowe

6

1 reference

Europe PubMed Central

21 June 2017

M Keith Howard

10

1 reference

Europe PubMed Central

21 June 2017

language of work or name

0 references

publication date

29 June 2012

1 reference

Europe PubMed Central

21 June 2017

1 reference

Europe PubMed Central

21 June 2017

30

1 reference

Europe PubMed Central

21 June 2017

37

1 reference

Europe PubMed Central

21 June 2017

5533-5540

1 reference

Europe PubMed Central

21 June 2017

Avian influenza. Warning of H5N1 resurgence surprises community

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

Longevity of the protective immune response induced after vaccination with one or two doses of AS03A-adjuvanted split H5N1 vaccine in ferrets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

Comparison of single, homologous prime-boost and heterologous prime-boost immunization strategies against H5N1 influenza virus in a mouse challenge model.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: Application for potency determinations of inactivated whole virus and subunit vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

Pre- or post-pandemic influenza vaccine?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

A vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

Influenza virus-like particles containing M2 induce broadly cross protective immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

Cationic liposome-DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

Influenza and the challenge for immunology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

T cell responses are better correlates of vaccine protection in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

Antibodies and B cell memory in viral immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

Cytokines involved in B-cell differentiation and their sites of action

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

Ab and T cell epitopes of influenza A virus, knowledge and opportunities

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

Vaccinate before the next pandemic?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.043

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2012.06.043

1 reference

Europe PubMed Central

21 June 2017

1 reference

Europe PubMed Central

21 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30418715&oldid=1972811511"